Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UJM8

UPID:
HAOX1_HUMAN

ALTERNATIVE NAMES:
Glycolate oxidase; Glyoxylate oxidase

ALTERNATIVE UPACC:
Q9UJM8; Q14CQ0; Q9UPZ0; Q9Y3I7

BACKGROUND:
The enzyme 2-Hydroxyacid oxidase 1, with alternative names Glycolate oxidase and Glyoxylate oxidase, is pivotal in metabolizing glycolate to glyoxylate, facilitating the synthesis of glycine. This process is essential for the detoxification of glyoxylate, averting its conversion to oxalate, which can lead to kidney stones. The enzyme's ability to also oxidize glyoxylate and various long-chain hydroxyacids, albeit with lower efficiency, underscores its metabolic versatility.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of 2-Hydroxyacid oxidase 1 unveils potential avenues for therapeutic development. Its critical role in managing glyoxylate levels and preventing kidney stone formation positions it as a promising target for drug discovery and therapeutic applications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.